This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Care Funds Suffer Amid Insurer Warnings

Headlines about health care funds catching the flu have been no joke this week for investors.

This week the, biggest U.S. health insurer, UnitedHealth Group (UNH), actually complained that higher-than-expected influenza rates may impact first quarter earnings.

The bottom dropped out for the sector, as UnitedHealth's competitors Humana (HUM) and WellPoint (WLP) cut their full-year forecasts. Two of the largest adverse factors for these companies are rate competition for market share to attract Medicare prescription-drug-plan patients and higher-than-expected medical costs.

A low-interest-rate environment is also a negative to insurance companies, especially as medical-cost inflation routinely outpaces broader measures. Insurers are earning less interest income on the securities they buy with your health-care premium money.

Excluding inverse funds, the average health-care fund we track fell 2.6% for the five trading days ending March 13.

The worst-performing fund this week is the iShares Dow Jones U.S. Healthcare Providers Index (IHF). This ETF lost 11% as holdings of Humana amputated 32% of shareholder value, WellPoint sliced off 31%, and UnitedHealth Group declined 16%.

In second place, the HealthShares Emerging Cancer ETF (HHJ) lost 9.7% for the period. In a breathtaking drop of 88%, the fund's holding in Keryx Biopharmaceuticals (KERX) was severely punished after its diabetic kidney drug failed to pass final-stage trials.

Similarly, Progenics Pharmaceuticals' (PGNX) stock tumbled 64% after its colon drug didn't beat the placebo in a trial.

The third-place fund, Fidelity Select Medical Delivery Portfolio (FSHCX), holds the three health insurers mentioned above, along with Aspect Medical Systems (ASPM), a stock that lost just over half its value this week.

The New England Journal of Medicine reported that Aspect's Bispectral Index System project, used in 60% of hospitals, didn't reduce awareness during surgery as advertised.

Worst-Performing Health Care Funds
Ranked by returns for the week ending March 13

Fund Ticker Rating Fund Type 1 Week Total Return
iShares DJ US Healthcare Providers Index Fund IHF B+ ETF -10.53%
HealthShares Emerging Cancer ETF HHJ E+ ETF -9.72%
Fidelity Select Medical Delivery Portfolio FSHCX C Open-End -9.23%
HealthShares Autoimmune-Inflammation ETF HHA U ETF -8.31%
HealthShares Ophthalmology ETF HHZ U ETF -7.92%
PowerShares Dynamic Healthcare Services Portfolio PTJ B- ETF -7.85%
HealthShares Orthopedic Repair ETF HHP U ETF -6.57%
Healthshares Infectious Disease ETF HHG U ETF -5.90%
ICON Healthcare Fund ICHCX D- Open-End -5.81%
HealthShares Composite ETF HHQ U ETF -5.63%

Source: Bloomberg.
For an explanation of our ratings, click here.

The best-performing list is dominated by biotechnology funds. The king of the hill is ProFunds Biotechnology UltraSector ProFund (BIPIX) at 4.13%. The fund is leveraged 150% to the Dow Jones U.S. Biotechnology Index, allocated to 73% biotechnology and 24% pharmaceuticals.

Both this fund and the third-place fund, Biotech HOLDRs Trust (BBH), have large holdings of industry leaders Amgen (AMGN), Gilead (GILD), Genentech (DNA), and Biogen Idec (BIIB).

Higher-than-expected costs at health-care companies may translate into positive revenue surprises for pharmaceutical and biotech businesses.

UltraShort Health Care ProShares (RXD) gained 4.10% with 200% negative leverage to the Dow Jones U.S. Health Care Index. The fund bets against insurers and medical-delivery stocks such as Humana and WellPoint.

Index member Immucor (BLUD) drained off 20% of stockholder value with the disclosure that the company's acquisition of BioArray may dilute earnings for 2008.

Best Performing Healthcare Funds
Ranked by returns for the week ending March 13

Fund Ticker Rating Fund Type 1 Week Total Return
ProFunds Biotechnology UltraSector ProFund BIPIX C+ Open-End 4.13%
UltraShort Health Care ProShares RXD D ETF 4.10%
Biotech HOLDRs Trust BBH C- ETF 2.76%
Powershares Dynamic Pharmaceuticals Portfolio PJP D ETF 1.08%
AMIDEX Cancer Innovations & Healthcare Mutual Fund CNCRX E- Open-End 0.53%
First Trust AMEX Biotechnology Index Fund FBT D ETF 0.42%
Healthshares European Drugs ETF HRJ U ETF 0.37%
iShares Dow Jones US Medical Devices Index Fund IHI C ETF 0.30%
SPDR S&P Biotech ETF XBI C+ ETF -0.18%
Eaton Vance Worldwide Health Sciences Fund EMHSX D- Open-End -0.21%

Source: Bloomberg
For an explanation of our ratings, click here.

Stay healthy!

Kevin Baker became the senior financial analyst for TSC Ratings upon the August 2006 acquisition of Weiss Ratings by, covering mutual funds. He joined the Weiss Group in 1997 as a banking and brokerage analyst. In 1999, he created the Weiss Group's first ratings to gauge the level of risk in U.S. equities. Baker received a B.S. degree in management from Rensselaer Polytechnic Institute and an M.B.A. with a finance specialization from Nova Southeastern University.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs